Upload
matthew-sarge
View
215
Download
1
Embed Size (px)
Citation preview
TA OGUNLESI (FWACP) 1
CHILDHOOD LEUKAEMIA
TA OGUNLESI (FWACP) 2
LEUKAEMIA
Heterogenous group of malignant disorders
Characterised by uncontrolled clonal proliferation
Accumulation of blasts cells in the bone marrow and body tissues
TA OGUNLESI (FWACP) 3
CLASSIFICATION
Acute Acute lymphoblastic leukemia (T-ALL &
B-ALL) Acute myeloid leukemia
Chronic Chronic myeloid leukemia Chronic lymphocytic leukemia
TA OGUNLESI (FWACP) 4
ACUTE LYMPHOBLASTIC LEUKAEMIA
A malignant (clonal) disease of the bone marrow in which early lymphoid precursors (blast cells) proliferate and replace the normal hematopoietic cells of the marrow.
TA OGUNLESI (FWACP) 5
ALL
Cancer of the blood affecting the LYMPHOCYTES.
85% of childhood leukaemia Commonest in the age 2-10 years Peak at 3-4 years. Commoner among males than females
(1.2:1) Commoner among whites than blacks
TA OGUNLESI (FWACP) 6
EPIDEMIOLOGY
In the US, ALL forms about 25% of all childhood cancers.
In Enugu, ALL formed 7.6% of all childhood cancers
Incidence is reported to be on the increase world wide for no known reason
TA OGUNLESI (FWACP) 7
AETIOLOGY
Exact aetiology is unknown Genetic predisposition include: Down syndrome Neurofibromatosis Ataxia-telangiectasia
Environmental predisposition include: Exposure to tobacco smoke Exposure to pesticide Exposure to ionizing irradiation
TA OGUNLESI (FWACP) 8
PATHOPHYSIOLOGY
The malignant cells of ALL are lymphoid precursor cells (ie, lymphoblasts) that are arrested in an early stage of development.
This arrest is caused by an abnormal expression of genes, often as a result of chromosomal translocations.
TA OGUNLESI (FWACP) 9
PATHOPHYSIOLOGY
The lymphoblasts replace the normal marrow elements, resulting in a marked decrease in the production of normal blood cells.
Consequently, anemia, thrombocytopenia, and neutropenia occur to varying degrees.
The lymphoblasts also proliferate in organs other than the marrow, particularly the liver, spleen, and lymph nodes.
TA OGUNLESI (FWACP) 10
CLINICAL FEATURES
Bone pains (Commonest) Arthritis and arthralgia Generalized Lymphadenopathy Hepatomegaly & Splenomegaly Enlarged thymus anterior mediastinal mass Easy bruising Severe anaemia Increased susceptibility to infections Testicular swelling
TA OGUNLESI (FWACP) 11
MANAGEMENT
1. Full blood count Reduced haemoglobin &
normochromic, normocytic anaemia, WBC
<1.0x109/l to >200x109/l, neutropenia and blast cells
Thrombocytopenia (<100x109/l).
TA OGUNLESI (FWACP) 12
TA OGUNLESI (FWACP) 13
TA OGUNLESI (FWACP) 14
INVESTIGATIONS
2. Bone marrow aspiration and trephine biopsy
· confirm acute leukaemia
(blast > 30%) usually hypercellular
TA OGUNLESI (FWACP) 15
INVESTIGATIONS
3. Cytochemical staining
)A Peroxidase :- * negative ALL * positive AML
B) Periodic acid schiff
*Positive ALL
* Negative AML
TA OGUNLESI (FWACP) 16
INVESTIGATIONS
4.Immunophenotyping
· identify antigens present on the blast cells
· determine whether the leukaemia is lymphoid or myeloid
· differentiate T-ALL and B-ALL
TA OGUNLESI (FWACP) 17
INVESTIGATIONS
5. Chest radiography · mediastinal mass - present in up to 70% of
patients with T -ALLIn childhood ALL bone lesions may also seen.
6.Lumbar puncture initial staging inv. to detect leukaemic cells
in the cerebrospinal fluid, indicating involvement of the CNS
Done in acute lymphoblastic leukemia
TA OGUNLESI (FWACP) 18
MANAGEMENT
SUPPORTIVE CARE Blood support :- Platelet con. for bleeding episodes or if the platelet
count is <10x109/l with fever Fresh frozen plasma if the coagulation screen
results are abnormal Packed red cell for severe anaemia (caution : if
white cell count is extremely high) Antibiotic therapy if infections are suspected
TA OGUNLESI (FWACP) 19
MANAGEMENT
Cytotoxic therapy involves 4 stages: Remission induction Intensification & consolidation Maintenance therapy CNS prophylaxis Combined therapy to forestall the
prevention of resistant leukaemic cells Therapy takes 2 to 3 years
TA OGUNLESI (FWACP) 20
MANAGEMENT
REMISSION Defined as absence of lymphadenopathy,
presence of normal peripheral blood counts, blast cells <5% in the bone marrow.
Drugs used: Vincristine, Prednisolone, L-asparaginase and IT Methotrexate, hydrocortisone & cytosine arabinoside
98% of cases achieve remission within 4 weeks of therapy
TA OGUNLESI (FWACP) 21
MANAGEMENT
CONSOLIDATION THERAPY Aimed to consolidate the gains of induced
remission to further eliminate remaining leukaemic cells
This has been shown to improve outcome Higher doses of drugs previously used for
induction of remission are used Several cycles of high dose Methotrexate,
doxorubicin or pulses of L-asparaginase.
TA OGUNLESI (FWACP) 22
MANAGEMENT
MAINTENANCE THERAPY Weekly Methotrexate Daily 6-Metacarptopurine Pulses of Vincristine & Prednisolone
Duration: 2 to 3 years
TA OGUNLESI (FWACP) 23
MANAGEMENT
CNS THERAPY The CNS is a sanctuary site for leukaemic
cells, hence specific treatment need to be directed at the CNS
Radiation is effective but flawed by many morbidities (so limited to children with high risk)
Intra-thecal high dose cytotoxic drugs (Methotrexate, Cytosine arabinoside/ Hydrocortisone) are equally effective
TA OGUNLESI (FWACP) 24
PROGNOSIS
70% of cases are curable with chemotherapy and bone marrow transplantation
Poor prognostic factors: Age <1 year or >10 years High WBC count (>50,000/mm3) T-Cell ALL High Haematocrit (PCV >30%)